Heidelberg Pharma AG (XTER:HPHA) Total Long-Term Assets : €13.55 Mil (As of Feb. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Heidelberg Pharma AG's Total Long-Term Assets for the quarter that ended in Feb. 2024 was €13.55 Mil.

Heidelberg Pharma AG Total Long-Term Assets Historical Data

The historical data trend for Heidelberg Pharma AG's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Total Long-Term Assets Chart

Heidelberg Pharma AG Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Total Long-Term Assets

Get a 7-Day Free Trial

11.40

12.09

12.72

12.70

13.72

Heidelberg Pharma AG Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Total Long-Term Assets	Get a 7-Day Free Trial															12.80	13.08	12.96	13.72	13.55

Heidelberg Pharma AG Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Heidelberg Pharma AG Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG (XTER:HPHA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Total Long-Term Assets

Comparable Companies

Traded in Other Exchanges

HPHA:Germany HPHA:Germany HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Executives

Prof. Dr. Andreas Pahl

Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines